ÂÜÀòÂÒÂ×

Kumiko Iwabuchi serves as Principal Scientist at Shinobi Therapeutics since April 2023, focusing on genome-engineered hypoimmune iPSCs and ectopic gene expression. Previously, Kumiko held the position of Senior Scientist at Synthego Corporation, delivering over 200 customized cell lines and supervising trainees in gene editing. Experience includes postdoctoral roles at JICHI Medical University, where 71 iPSC lines were generated, and the Center for iPS Cell Research and Application, conducting CRISPR off-target analysis and TCR/BCR repertoire studies. Additional positions include postdoctoral research at Roswell Park Cancer Institute and Harvard Medical School, as well as research fellowships at Joslin Diabetes Center and Boston Children's Hospital. Kumiko earned a PhD and a Master's in Medicine from Kyoto University and a Bachelor's in Law from Keio University.